Clinical Significance and Different Expression of Dipeptidyl Peptidase IV and Procalcitonin in Mild and Severe COVID-19

authors:

avatar Hamidreza Jamaati ORCID , * , avatar Payam Tabarsi ORCID , avatar Naghmeh Bahrami ORCID , avatar Fatemeh Yasari , avatar Mohammad Varahram , avatar Mehdi Kazempour Dizaji , avatar Seyed Mohammadreza Hashemian , avatar Mahya Daustany , avatar Maral Emami , avatar Sadegh Shirian ORCID , avatar Ladan Masumi , avatar Amir Rasouli , avatar Armita Narimani , avatar Nasser Ahmadian , avatar Abdolreza Mohamadnia ORCID 1 , avatar Ali Akbar Velayati

PhD of Molecular Medicine, Virology Research Center, National Research Institute of Tuberculosis & Lung Disease (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran
Journal of Cellular & Molecular Anesthesia: Vol.6, issue 2; e149671
published online: May 15, 2021
article type: Original Articles
DOI: https://doi.org/10.22037/jcma.v6i2.34671

how to cite: Jamaati H, Tabarsi P, Bahrami N, Yasari F , Varahram M , et al. Clinical Significance and Different Expression of Dipeptidyl Peptidase IV and Procalcitonin in Mild and Severe COVID-19. J Cell Mol Anesth. 2021;6(2):e149671. https://doi.org/10.22037/jcma.v6i2.34671.

Abstract

Background: Coronavirus has become a global concern in 2019-20. The virus belongs to the coronavirus family, which has been able to infect many patients and victims around the world. The virus originated in the Chinese city of Wuhan, which eventually spread around the world and became a pandemic. Materials and Methods: A total of 60 Patients with severe (n=30) and mild (n=30) symptoms of COIVD-19 were included in this study. Peripheral blood samples were collected from the patients. Real-time PCR was used to compare the relative expression levels of Procalcitonin and dipeptidyl peptidase IV (DPPIV) in a patient with severe and mild Covid-19 infection. Results: Procalcitonin and dipeptidyl peptidase IV markers in the peripheral blood of patients with severe symptoms, were positive in 29 (96.60%) and 26 (86.60%), respectively (n=30); however, positive rates in the mild symptoms patients group were 27 (90%) and 25 (83.30%), respectively. There was a statistically significant difference between these two groups in terms of DDPIV and Procalcitonin (p<0.001). Conclusion: Procalcitonin and DPPIV increase in patients with COVID-19 infection, significantly higher in the patients with more severe clinical symptoms than those with milder ones. More studies will be needed to verify the reliability of the current findings. Keywords: Procalcitonin, DPPIV, Severe symptoms, Mild symptoms, COVID-19

References

  • 1.

    References are in the PDF file of the article.